Antidepressant agents in short bowel syndrome
Related Experiment Video
Updated: Apr 20, 2026

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
Published on: June 6, 2025
Elodie Faye1, Olivier Corcos2, Frédérique Lancelin3
1VariaPsy, Variability of the Response to Psychotropic Drugs, Paris Descartes and Paris Diderot Universities, Paris, France; Unit of Therapeutic Research, Department of Internal Medicine, Lariboisière Hospital, Assistance Publique-Hôpitaux de Paris (APHP), Paris, France.
Purpose:
This study aimed to determine whether short small intestine modifies antidepressant concentrations.
Methods:
The Css values and concentration-dose ratios (CDRs) of citalopram or escitalopram, administered orally or intravenously, were determined in patients with short bowel syndrome.
Findings:
Eight patients (6 males and 2 females) were included in the study. High CDRs were obtained in orally treated patients with >180 cm of small bowel and in those with >80 cm of small bowel and 50% of colon. Three patients had low Css values, including 1 patient who received intravenous treatment.
Implications:
The variability of drug absorption and metabolism makes prescribing SSRIs challenging in these patients.
More Related Videos
Related Concept Videos
Antidepressant Drugs: MAOIs and Other Agents
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
Drugs for Treatment of Constipation-Predominant IBS
Antidepressant Drugs: Overview

